- Home
- MQT vs ATAI Comparison
MQT vs ATAI Comparison
Compare MQT & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQT
- ATAI
- Stock Information
- Founded
- MQT 1992
- ATAI 2018
- Country
- MQT United States
- ATAI Germany
- Employees
- MQT N/A
- ATAI N/A
- Industry
- MQT Investment Bankers/Brokers/Service
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- MQT Finance
- ATAI Health Care
- Exchange
- MQT Nasdaq
- ATAI Nasdaq
- Market Cap
- MQT 228.6M
- ATAI 214.8M
- IPO Year
- MQT N/A
- ATAI 2021
- Fundamental
- Price
- MQT $10.32
- ATAI $1.52
- Analyst Decision
- MQT
- ATAI Strong Buy
- Analyst Count
- MQT 0
- ATAI 4
- Target Price
- MQT N/A
- ATAI $9.00
- AVG Volume (30 Days)
- MQT 52.5K
- ATAI 2.2M
- Earning Date
- MQT 01-01-0001
- ATAI 11-13-2024
- Dividend Yield
- MQT 4.60%
- ATAI N/A
- EPS Growth
- MQT N/A
- ATAI N/A
- EPS
- MQT N/A
- ATAI N/A
- Revenue
- MQT N/A
- ATAI $331,000.00
- Revenue This Year
- MQT N/A
- ATAI $44.72
- Revenue Next Year
- MQT N/A
- ATAI N/A
- P/E Ratio
- MQT N/A
- ATAI N/A
- Revenue Growth
- MQT N/A
- ATAI N/A
- 52 Week Low
- MQT $8.59
- ATAI $1.03
- 52 Week High
- MQT $10.67
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- MQT 40.07
- ATAI 57.65
- Support Level
- MQT $10.36
- ATAI $1.53
- Resistance Level
- MQT $10.62
- ATAI $1.95
- Average True Range (ATR)
- MQT 0.09
- ATAI 0.20
- MACD
- MQT -0.00
- ATAI 0.03
- Stochastic Oscillator
- MQT 14.29
- ATAI 52.22
About MQT Blackrock MuniYield Quality Fund II Inc.
BLACKROCK MUNIYIELD QUALITY FUND II, INC. is a closed-end fund. Its objective is to provide shareholders with as high a level of current income exempt from federal income taxes as is consistent with its investment policies and prudent investment management. It invests in various sectors such as Transportation, Utilities, Health, County/City/Special District/School District, Education, and Housing.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.